Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in PV Patients. Two – year results from the First Prospective Randomized Controlled Trial
PV Reporter Interviews Dr. Jean Jacques Kiladjian at ASH 2017
Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in PV Patients. Two – year results from the First Prospective Randomized Controlled Trial